# Leuprolide Acetate Promotes Sensory Recovery and Modulates Dorsal Root Ganglion Responses After Sciatic Nerve Transection in Rats

**Authors:** Irma Hernández-Jasso, Denisse Calderón-Vallejo, José Ávila-Mendoza, David Epardo, Jerusa E. Balderas-Márquez, Carlos Arámburo, J. Luis Quintanar, Carlos G. Martínez-Moreno

PMC · DOI: 10.3390/brainsci16030332 · 2026-03-20

## TL;DR

Leuprolide acetate helps recover cold sensitivity and supports nerve healing after sciatic nerve injury in rats.

## Contribution

LA's novel role in promoting sensory recovery and modulating DRG responses after nerve injury is demonstrated.

## Key findings

- LA promotes recovery of cold sensitivity after sciatic nerve injury.
- LA improves retrograde axonal transport and reduces inflammation in dorsal root ganglia.
- LA modulates pro-regenerative gene expression in peripheral nerve injury.

## Abstract

What are the main findings?
•LA promotes selective recovery of cold sensitivity after sciatic nerve transection.•LA enhances retrograde axonal transport after sciatic nerve transection.•LA attenuates reactive gliosis and macrophage activation in dorsal root ganglia after sciatic nerve transection.•LA modulates the expression of key pro-regenerative genes in peripheral nerve injury.

LA promotes selective recovery of cold sensitivity after sciatic nerve transection.

LA enhances retrograde axonal transport after sciatic nerve transection.

LA attenuates reactive gliosis and macrophage activation in dorsal root ganglia after sciatic nerve transection.

LA modulates the expression of key pro-regenerative genes in peripheral nerve injury.

What is the implication of the main finding?
•The results suggest that LA could be a promising therapeutic strategy to improve sensory recovery and neuroregeneration following peripheral nerve injury.

The results suggest that LA could be a promising therapeutic strategy to improve sensory recovery and neuroregeneration following peripheral nerve injury.

Background/Objectives: Sciatic nerve injuries are among the most common classes of peripheral nerve harm and have a strong impact on quality of life, as well as a significant negative economic impact for patients, society, and governments, since they represent a frequent cause of work-related disabilities and sick leave applications. Following nerve injury, neurons, Schwann, and satellite cells undergo marked changes in phenotype, metabolic activity, neuronal survival, nervous transmission, and an exacerbated activation of the inflammatory response. Leuprolide acetate (LA), a clinically available agonist of gonadotropin-releasing hormone (GnRH), has shown clear neurotrophic properties and is considered a novel potential candidate for treating neural injuries, including sciatic nerve pathologies. This study aimed to analyze the effect of LA treatment on sensory function and dorsal root ganglia (DRG) changes in a rat sciatic nerve full-transection (SNT) model. Methods: Variations in cold and heat sensitivity were assessed using the thermal plate test, while DRG tissue sections were examined for modifications in reactive gliosis by immunofluorescence analysis, and axonal transport using a retrograde tracer. Also, changes in the expression of pro-regenerative genes Stat3, Socs3, Fos, Jun, Atf4, and Limk1 were quantified by qPCR. Results: Our results showed that LA treatment exerted a distinct neurotrophic effect, since it promoted the specific recovery of cold sensitivity, improved axonal transport, regulated the inflammatory response, and modulated the exacerbated expression of pro-regenerative genes in the SNT model. Conclusions: These findings indicate that LA therapy may have the potential to improve sensory recovery in patients with sciatic nerve injuries.

## Linked entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], SOCS3 (suppressor of cytokine signaling 3) [NCBI Gene 9021], FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353], JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725], ATF4 (activating transcription factor 4) [NCBI Gene 468], LIMK1 (LIM domain kinase 1) [NCBI Gene 3984]
- **Chemicals:** Leuprolide acetate (PubChem CID 657180)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, Gnrhr (gonadotropin releasing hormone receptor) [NCBI Gene 81668] {aka GH1, Lhrhr}, Cntf (ciliary neurotrophic factor) [NCBI Gene 25707], Ppia (peptidylprolyl isomerase A) [NCBI Gene 25518] {aka CYCA, CyP-A, p1B15, p31}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 25125], Ngf (nerve growth factor) [NCBI Gene 310738] {aka Ngfb, beta-NGF}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, Fos (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 314322] {aka c-fos}, GNRH1 (gonadotropin releasing hormone 1) [NCBI Gene 2796] {aka GNRH, GRH, LHRH, LNRH}, Trpm8 (transient receptor potential cation channel, subfamily M, member 8) [NCBI Gene 171384] {aka CMR1}, Aif1 (allograft inflammatory factor 1) [NCBI Gene 29427] {aka BART-1, Bart1, iba1, mrf-1}, Socs3 (suppressor of cytokine signaling 3) [NCBI Gene 89829] {aka Cish3, Socs-3, Ssi-3}, Ntf3 (neurotrophin 3) [NCBI Gene 81737], Bdnf (brain-derived neurotrophic factor) [NCBI Gene 24225], SOCS3 (suppressor of cytokine signaling 3) [NCBI Gene 9021] {aka ATOD4, CIS3, Cish3, SOCS-3, SSI-3, SSI3}, Gnrh1 (gonadotropin releasing hormone 1) [NCBI Gene 25194] {aka Gnrh, Gnrha, Lhrh, Rgnrhg1, SH-4}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 24516], FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, Limk1 (LIM domain kinase 1) [NCBI Gene 65172], Dnase1 (deoxyribonuclease 1) [NCBI Gene 25633], LIMK1 (LIM domain kinase 1) [NCBI Gene 3984] {aka LIMK, LIMK-1}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, Gfap (glial fibrillary acidic protein) [NCBI Gene 24387]
- **Diseases:** nerve (MESH:C537568), peripheral nerve injuries (MESH:D059348), neuroinflammatory (MESH:D000090862), spinal cord injury (MESH:D013119), ischemia (MESH:D007511), spinal cord (MESH:D013118), nerve transection (MESH:D020221), injury to (MESH:D014947), neuropathic pain (MESH:D009437), peripheral nerve harm (MESH:D010523), nerve damage (MESH:D000080902), chronic pain (MESH:D059350), neuronal damage (MESH:D009410), brain trauma (MESH:D000070642), SN (MESH:D020426), bone fractures (MESH:D050723), inflammation (MESH:D007249), neurological damage (MESH:D020196), hypoxia (MESH:D000860), multiple sclerosis (MESH:D009103), precocious puberty (MESH:D011629), gliosis (MESH:D005911), pathologies (MESH:D005598)
- **Chemicals:** DAPI (MESH:C007293), PFA (MESH:C003043), TRIzol (MESH:C411644), AlexaFluor-568 (-), silane (MESH:D012821), Triton X-100 (MESH:D017830), SYBR Green (MESH:C098022), FSH (MESH:D005640), sucrose (MESH:D013395), aluminum (MESH:D000535), Dextran (MESH:D003911), NaCl (MESH:D012965), Acetate (MESH:D000085), xylazine (MESH:D014991), phosphate (MESH:D010710), PBS (MESH:D007854), minocycline (MESH:D008911)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025228/full.md

---
Source: https://tomesphere.com/paper/PMC13025228